PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.81%
EBIT growth similar to AGEN's 35.97%. Walter Schloss might infer both firms share similar operational efficiencies.
36.41%
Operating income growth similar to AGEN's 35.97%. Walter Schloss would assume both share comparable operational structures.
439.57%
Net income growth above 1.5x AGEN's 43.57%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
440.81%
EPS growth above 1.5x AGEN's 46.55%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
440.81%
Diluted EPS growth above 1.5x AGEN's 46.55%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
681.03%
OCF growth above 1.5x AGEN's 44.30%. David Dodd would confirm a clear edge in underlying cash generation.
681.03%
FCF growth above 1.5x AGEN's 44.37%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1209.68%
10Y OCF/share CAGR above 1.5x AGEN's 75.59%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
1209.68%
5Y OCF/share CAGR above 1.5x AGEN's 90.11%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
1209.68%
3Y OCF/share CAGR above 1.5x AGEN's 76.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
934.70%
Net income/share CAGR above 1.5x AGEN's 73.45% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
934.70%
5Y net income/share CAGR above 1.5x AGEN's 88.80%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
934.70%
3Y net income/share CAGR above 1.5x AGEN's 75.77%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-244.00%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-244.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-244.00%
Negative 3Y equity/share growth while AGEN is at 72.52%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
Asset growth above 1.5x AGEN's 7.63%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
26.94%
1.25-1.5x AGEN's 23.14%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
3.22%
We have some new debt while AGEN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.